Komori
Share Issuance and Disposal4564OncoTherapy Science,Inc.Pharmaceuticals

Notice Regarding the Record Date for and Convocation of an Extraordinary General Meeting of Shareholders and Reduction of Stated Capital

Of the stated capital of ¥335,654,000, ¥285,654,000 will be reduced and transferred to other capital surplus. Stated capital after the reduction is expected to be ¥50,000,000, but the number of shares and shareholders’ ownership percentages will remain unchanged.

Worth reading
27Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
285654000
yen
Wording
Conditional
How definitive the wording is.

Details of issuance or disposal

発行済株式総数

No change

0% (the total number of issued shares will not change)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Procedures under the Corporate Code of Conduct
At the extraordinary general meeting of shareholders scheduled for 10 February 2027, the matter concerning the reduction of stated capital will be submitted for approval, and shareholder approval is expected.
Impact on Business Performance
The change will have no impact on the performance of the Group for the fiscal year ending March 2027.
Details of issuance or disposal
ItemDetails
Dilution Rate0% (the total number of issued shares will not change)
Total number of issued sharesNo change
Procedures under the Corporate Code of ConductAt the extraordinary general meeting of shareholders scheduled for 10 February 2027, the matter concerning the reduction of stated capital will be submitted for approval, and shareholder approval is expected.
Impact on Business PerformanceThe change will have no impact on the performance of the Group for the fiscal year ending March 2027.
Items this document does not state (24)
Type of issuance or disposalNumber of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offering

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To ensure flexibility and agility in the Company's future capital policy.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Record Date for and Convocation of an Extraordinary General Meeting of Shareholders and Reduction of Stated Capital | OncoTherapy Science,Inc. (4564) timely disclosure | Komori